There is a reason why the initial papers are coming out in China. Granted, China's biotech is young and getting better every year, but there is a cottage industry of trials initiated in China due to laxer review and ethical standards there; a trial like this in the US would have taken years of paperwork to clear the FDA.

Granted... the FDA and other pharmas do spend a lot of time, money and manpower to monitor clinical trials in China because eventually, the pharmas attempt to use these trials, conducted "over there" at lesser costs, to get approval for clinical use in the US through the FDA...